  In ophthalmology, intravitreal operative medication therapy (IVOM) is a
widespread treatment for diseases related to the age-related macular
degeneration (AMD), the diabetic macular edema (DME), as well as the retinal
vein occlusion (RVO). However, in real-world settings, patients often suffer
from loss of vision on time scales of years despite therapy, whereas the
prediction of the visual acuity (VA) and the earliest possible detection of
deterioration under real-life conditions is challenging due to heterogeneous
and incomplete data. In this contribution, we present a workflow for the
development of a research-compatible data corpus fusing different IT systems of
the department of ophthalmology of a German maximum care hospital. The
extensive data corpus allows predictive statements of the expected progression
of a patient and his or her VA in each of the three diseases. We found out for
the disease AMD a significant deterioration of the visual acuity over time.
Within our proposed multistage system, we classify the VA progression into the
three groups of therapy "winners", "stabilizers", and "losers" (WSL scheme).
Our OCT biomarker classification using an ensemble of deep neural networks
results in a classification accuracy (F1-score) of over 98 %, enabling us to
complete incomplete OCT documentations while allowing us to exploit them for a
more precise VA modelling process. Our VA prediction requires at least four VA
examinations and optionally OCT biomarkers from the same time period to predict
the VA progression within a forecasted time frame, whereas our prediction is
currently restricted to IVOM / no therapy. While achieving a prediction
accuracy of up to 69 % (macro average F1-score) when considering all three
WSL-based progression groups, this corresponds to an improvement by 11.2 % in
comparison to our ophthalmic expertise (57.8 %).
